子宮頸癌トータルマネジメント

出版社： メディカルレビュー社
著者：
発行日： 2014-12-01
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784779213892
電子書籍版： 2014-12-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,650 円(税込)

購入する

目次

  • 子宮頸癌トータルマネジメント

    ―目次―

    第I章　子宮頸癌を取り巻く変化
    　〔巻頭対談〕子宮頸癌を取り巻く変化
    　　　　　　　　―早期発見・早期治療から予防へ―

    第II章　子宮頸癌のトータルマネジメント
    　1．ハイリスクHPVの特徴
    　2．産婦人科実地医家における予防対策
    　沖縄県の現状と課題
    　3．病診連携で推進する子宮頸癌対策
    　4．産婦人科腫瘍専門医が担う啓発
    〔特別寄稿〕産婦人科医の立場で行う10代からのがん教育

    第III章　HPVワクチン―蓄積されたエビデンスの価値―
    　1．患者動向の変化
    　2．抗体価持続のエビデンス
    　3．医療経済効果
    　4．HPV型を問わない予防効果―クロスプロテクションを検証する―
    　5．本邦におけるHPVワクチンのエビデンス
    　6．子宮頸部円錐切除術後のワクチン接種
    〔特別寄稿〕成人女性のワクチン接種

    第IV章　治療と今後の展望
    　1．子宮頸がん検診の進化―本邦の検診事情と将来像―
    　京都府における子宮頸がん検診の現状と課題
    　2．最新の子宮頸癌治療
    　3．〔最新トピック座談会〕次世代の子宮頸癌予防と治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第II章 子宮頸癌のトータルマネジメント

P.7 掲載の参考文献
1) Smith JS, Lindsay L, Hoots B, et al : Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions : a meta-analysis update Int J Cancer 2007, 121:621-32
 
2) Matsumoto K, Yoshlkawa H : Human papillomavirus infection and the risk of cervical cancer in Japan. J Obstet Gynaecol Res 2013 : 39 : 7-17
 
3) Onuki M, Matsumoto K, Satoh T, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer, Cancer Sci 2009, 100 : 1312-6
 
4) Khan MJ, castle PE, Lonncz AT, et al The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97 : 1072-9
PubMed
5) 日本産科婦人科学会, 日本産婦人科医会編集・監修 : 産婦人科診療ガイドライン-婦人科外来編 2014. pp 38-41, 2014
 
6) Matsumoto K, Oki A, Furuta R, et al : Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 2011 ; 128 : 2898-910
 
7) Tase T, Sato S, Wada Y, et al : Prevalence of Human Papillomavirus Type 18 DNA in Adenocarcinoma and Adenosquamous Carcinoma of the Uterine Cervix Occurring in Japan. Tohoku J Exp Med 1988 ; 156 : 47-53
 
8) Kurman RJ, Schiffman MH, Lancaster WD, et al : Analysis of individual human papillomavirus types in cervical neoplasia : a possible role for type 18 in rapid progression. Am J Obstet Gynecol 1988 ; 159 : 293-6
 
P.10 掲載の参考文献
1) 子宮頸癌取扱い規約編集会編 : 子宮頸癌取扱い規約とその解説 (第1版). 金原出版, 東京, pp 29-32, 1982
 
2) Richart, R M Natural history of cervical intraepithelial neoplasia.Clin Obstet. Gynecol 1967 ; 10 : 748-84
 
3) National Cancer Instltute Workshop : The 1988 Bethesda System for reporting cervical/vaginal cytological diagonoses. JAMA 1989 ; 262 : 931-4
 
4) 日本産科婦人科学会・日本産婦人科医会 編集・監修 : 産婦人科診療ガイドライン-婦人科外来編2014 pp 42-44, 2014
 
5) Moscicki AB, Shiboski S, Hills HK, et al : Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004 ; 364 : 1678-83
 
6) Matsumoto K, Oki A, Furuta R, et al : Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 2011 ; 128 : 2898-910
 
7) Klaes R, Woerner SM, Ridder R, et al : Detection of high-risk cervical intraepithelial neoplasia and cervical Cancer by amplication of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999 ; 59 : 6132-6
 
8) Khan MJ, Castle PE, Lorincz AT, et al The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Natl Cancer Inst 2005 ; 97 : 1072-9
PubMed
P.12 掲載の参考文献
1) 日本産科婦人科学会, 日本産婦人科医会編集・監修 : 産婦人科診療ガイドライン-婦人科外来編 2014. p.38, 2014
 
P.18 掲載の参考文献
1) 日本産科婦人科学会, 日本産婦人科医会編集・監修 : 産婦人科診療ガイドライン-婦人科外来編 2014
 
2) Khan MJ, et al : The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005 ; 97 : 1072-9
PubMed
3) Matsumoto K, Oki A, Furuta R, et al : Japan HPV and cervical cancer study group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 2011 ; 128 : 2898-910
 
4) Tsoumpou I, Arbyn M, Kyrgiou M, et al : p16 (INK4a) immunostaining in cytological and histological specimens from the uterine cervix : a systematic review and meta-analysis. Cancer Treat Rev 2009 ; 35 : 210-20
 
5) Schmidt D, Bergeron C, Denton KJ, et al : European CINtec Cytology Study Group. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology : results from the European equlvocal or mildly abnormal Papanicoiaou cytology study. Cancer Cytopathol 2011 ; 119 : 158-66
 
6) Fujii T, Saito M, Hasegawa T, et al : Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens : a Japanese Gynecologic Oncology Group study. Int J Clin Oncol 2014 Apr 18 [Epub ahead of print]
 
7) Darragh TM, Colgan TJ, Cox JT, et al : Members of LAST Project Work Groups : The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions : background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012 ; 16 : 205-42
 
P.20 掲載の参考文献
1) Hildesheim A, Wang SS : Host and viral genetics and risk of cervical cancer a review. Virus Res 2002 ; 89 : 229-40
 
2) Matsumoto K, Yoshikawa H : Human papillomavirus infection and the risk of cervical cancer in Japan. J Obstet Gynaecol Res 2013 ; 39 : 7-17
 
3) Rebolj M, Helmerhorst T, Habbema D, et al : Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia : population based cohort study, BMJ 2012 31 ; 345 : e6855
 
4) 日本婦人科腫瘍学会編子宮頸癌治療ガイドライン2011年版. 金原出版, 東京, pp. 165-170, 2011
 
5) Elit L, Fyles AW, Devries MC, et al : Follow-up for women after treatment for cervical cancer : a systematic review. Gynecol Oncol 2009 ; 114 : 528-35
 
6) Boduruka-Bevers D, Morris M, Eifel PJ, et al : Posttherapy surveillance of women with cervical cancer : an outcomes analysis. Gynecol Oncol 2000 ; 78 : 187-93
 
7) Gadducci A, Tana R, Coslo S, et al : The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer : a review of the literature. Crit Rev Oncol Hematol 2008 ; 66 : 10-20
 
8) Cervical Cancer Guideline (Version 1, 2010). NCCN Clinical Practice Guidelines in Oncology
 
9) Kizer NT, Zighelboim I, Case AS, et al : The role of PET/CT in the management of patients with cervical cancer : practice patterns of the members of the Society of Gynecologic Oncologists. Gynecol Oncol 2009 ; 114 : 310-4
 
P.25 掲載の参考文献
1) http://www.esgo.org/About_ESGO/Documents/Statement_HPV.pdf
 
2) http://www.cdcgov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_Cid=mm5920a4_e
 
3) http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Adolescent_Health_Care/Human_Papillomavirus_Vaccination
 
4) Siddiqui M : Cervical Cancer Vaccination : A New Hope, AKMMC J 2011 ; 2 : 26-31
 
5) 平成24年度 厚生労働科学研究費補助金 (がん臨床研究事業), 地方自治体および地域コミュニティー単位の子宮頸がん予防対策が若年女性の意識と行動に及ぼす効果の実効性の検証 (研究代表者 宮城悦子) 総括・分担研究報告書
 
6) Miyagi E, Sukegawa A, Motoki Y, et al : Attitudes toward cervical cancer screening among women receiving HPV vaccination in a university hospital-based community : interim two-year follow-up results : J Obstetrics Gynaecol Res. Published online : 15 JAN 2014 ; DOI : 10, 1111/jog, 12288
 
P.29 掲載の参考文献
1) 足立春雄, 須川佶, 石塚直隆, 滝一郎, 磯島晋三, 友田豊, 川島吉良, 前山昌男, 倉智敬一, 森憲正 : 子宮頸癌. 新婦人科学 pp. 426-448, 1977
 
2) Schiffman MH, Brinton LA : Epidemiology Blaustein's Pathology of the Female Genital Tract. 4th ed, RJ Kurman pp. 1199-1223, 1994
 
3) Buckley JD, Harris RWC, Doll R, Vessey MP, Willlams PT, Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri Lancet 2 : 1010-1015, 1981
PubMed
4) Tominaga S : Cancer incidence in Japanese in Japan, Hawaii, and western United States. Natl Cancer Inst Monogr 69 : 83-92, 1985
PubMed
5) 第49回日本癌治療学会学術集会プログラム号. 46 : 201, 2011
 

第III章 HPVワクチン - 蓄積されたエビデンスの価値 -

P.34 掲載の参考文献
1) Lehtinen M, Paavonen J, Wheeler CM, et al : HPV PATRICIA Study Group, Overall efficacy of HPV-16/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical Intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol 2012 ; 13 : 89-99
 
2) Brotherton JM, Fridman M, May CL, et al : Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia : an ecological study. Lancet 2011 ; 377 : 2085-92
 
3) Lauri E, Markowitz, Susan Hariri, et al : Reduction in Human Papillomavirus (HPV) Prevalence Among YoungWomen Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. Journal of Infectious Diseases, OXFORD JOURNLA, 2013 June 19
 
4) Donovan B, Franklin N, Guy R, et al : Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia : analysis of national sentinel surveillance data. Lancet Infect Dis 2011 ; 11 : 39-44
 
5) Mesher D, Soldan K, Howell-Jones R, et al : Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England Vaccine 2013 (in press)
 
6) Wheeler CM, Castellsague X, Garland SM, et al : HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol 2012 ; 13 : 100-10
 
7) Palmroth J, Merikukka M, Paavonen J, et al : Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination Int J Cancer 2012 ; 131 : 2832-8
PubMed
P.37 掲載の参考文献
1) Safaeian M, Porrasc, Schiffman M, et al : Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010 ; 102 : 1653-62
 
2) Onuki M, Matsumoto K, Satoh T, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer, Cancer Sci 2009 ; 100 : 1312-6
 
3) Bosch FX, de Sanjose S : Chapter 1 : Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003 ; (31) : 3-13
 
4) Dunne EF, Unger ER, Sternberg M, et al : Prevalence of HPV infection among females in the United States. JAMA 2007 ; 297 : 813-9
PubMed
5) Lehtinen M, Paavonen J, Wheeler CM, et al : Overall efficacy of HPV-16/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 ; 13 : 89-99
PubMed
6) Kjaer SK, Sigurdsson K, Iversen OE, et al : A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009 ; 2 : 868-78
 
7) Einstein MH, Baron M, Levin MJ, et al : comparative immunogenicity and safety of human papillomavirus (HPV) -16/18 vaccine and HPV-6/11/16/18 vaccine : follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years, Hum Vaccin 2011 ; 7 : 1343-58
 
8) Roteli-Martins CM, Naud P, De Borba P, et al : Sustained immunogenicity and efficacy of the HPV-16/18 ASO4-adjuvanted vaccine : up to 8.4 years of follow-up. Hum Vaccin Immunother 2012 ; 8 : 390-7
 
9) Naud P, et al : HPV-16/18 vaccine : Sustained immunogenicity and efficacy up to 9.4 years. 27th International Papillomavirus Conference 2011, Berlin, Germany
 
10) Olsson SE, Villa LL, Costa RL, et al : Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine, Vaccine 2007 ; 25 : 4931-9
 
11) Nygard M, Saah A, Munkc, et al : A long-term follow-up study of the immunogenicity of the quadrivalent HPV (qHPV) vaccine in Scandinavia and Iceland. 28th International Papillomavirus Conference 2012, Puerto Rico
 
P.39 掲載の参考文献
1) Franceschi S (WHO, IARC), EUROGIN Roodmap toward aconsensus. EUROGIN 2008
 
2) Armstrong EP : Prophylaxls of cervical cancer and related cervical disease : a review of thecost-effectiveness of vaccoination against oncogenic HPV types, J Managcare Pharm 2010 ; 16 : 217-30
 
3) Konno R, Sasagawa T, Fukuda T, et al : Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer 2010 ; 20 : 385-92
 
4) 今野良, 笹川寿之, 福田敬ほか : 日本人女性における子宮頸癌予防ワクチンの費用効果分析. 産婦人科治療 2008 ; 97 : 530-42
 
5) 荒川一郎, 新野由子 : 若年女性の健康を考える 子宮頸がん予防ワクチン接種の意義と課題, 厚生の指標 2009 ; 56 : 1-6
 
6) 曽根智史 : がん対策の医療経済的評価に関する研究 : 平成20-22年度総合研究報告書 : 厚生労働科学研究費補助金がん臨床研究事業. 2011
 
P.42 掲載の参考文献
1) Ochi H, Kondo K, Matsumoto K, et al : Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 2008 ; 15 : 536-40
 
2) Draper E, Bissett SL, Howell-Jones R, et al Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011 ; 29 : 8585-90
 
3) Wheeler CM, Castellsague X, Garland SM, et al : Cross-protective efficacy of HPV-16/18 ASO4-adjuvanted vaccine against cervical infection and precancercaused by non-vaccine oncogenic HPV types 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol 2012, 13 : 100-10
 
4) Munoz N, Kjaer SK, Sigurdsson K, et al : Impact of human papillomavirus (HPV) -6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 ; 102 : 325-39
 
5) Einstein MH, Baron M, Levin MJ, et al : Comparison of the immunogenicity and safety of Cervarlx and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years Hum Vaccin. 2009 ; 5 : 705-19
 
6) Malagon T, Drolet M, Boily MC, et al : Cross-protective efficacy of two human papillomavirus vaccines a systematic review and meta-analysis. Lancet Infect Dis 2012 ; 12 : 781-9
PubMed
7) Romanowskl B : Long term protection against cervical infection with the human papillomavirus review of currently available vaccines. Hum Vaccin 2011 ; 7 : 161-9
 
8) Markowitz LE, Hariri S, Lin C, et al : Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination. Surveys, 2003-2010. J Infect Dis 2013 ; 208 : 385-93
PubMed
9) Kavanagh K, Pollock KG, Potts A, et al : Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014 ; 110 : 2804-11
PubMed
10) Einstein MH, Baron M, Levin MJ, et al : Comparison of the immunogenicity of the human papillomavirus (HPV) -16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011 ; 7 : 1359-73
 
11) Moscicki AB, Wheeler CM, Romanowski B, et al : Immune responses elicited by a fourth dose of the HPV-16/18 ASO4-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012 ; 31 : 234-41
 
P.44 掲載の参考文献
1) Onuki M, Matsumoto K, Satoh T, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009 ; 100 : 1312-6
 
2) Konno R, Tamura S, Dobbelaere K, et al : Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study, Cancer Sci 2011 : 102 : 877-82
 
3) Konno R, Tamura S, Dobbelaere K, et al : Efficacy of human papillomavirus type 16/18 ASO4-adjuvanted vaccine in Japanese women aged 20 to 25 years : final analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer 2010 ; 20 : 847-55
 
4) Konno R, Yoshikawa H, Okutani M, et al : 48-month efficacy of the HPV-16/18 ASO4-adjuvanted vaccine in young Japanese women. EUROGIN, 2012, Prague, Czech
 
5) Yoshikawa H, Ebihara K, Tanaka Y, et al : Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013 ; 104 : 465-72
 
P.46 掲載の参考文献
1) Kalliala I, et al, Cancer free survival after CIN treatment : comparisons of treatment methods and histology. Gynecol Oncol 2007 ; 105 : 228-233
 
2) Garland S, et al. SS 9-3, EUROGIN 2011, Portugal
 
P.48 掲載の参考文献
1) Bosch FX, de Sanjose S : Chapter 1 : Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003 : 3-13
 
2) Wang HK, Duffy AA, Broker TR, et al : Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev 2009 ; 23 : 181-94
 
3) Hildesheim A, Herrero R, Wacholder S, et al : Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection : a randomized trial. JAMA 2007 ; 298 : 743-53
 
4) Konno Ryo, Dobbelaere KO, Godeaux OO, et al : Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 ASO4-adjuvanted vaccine in Japanese women : interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer 2009 ; 19 : 905-11
 
5) FUTURE II Study Group : Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical. lesions. N Engl J Med 2007 ; 356 : 1915-27
 
6) Paavonen J, Naud P, Salmeron J, et al : Efficacy of human papillomavirus (HPV) -16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA) : final analysis of a double-blind, randomised study in young women. Lancet 2009 ; 374 : 301-14
 
7) Konno R, Tamura S, Dobbelaere K, et al : Efficacy of human papillomavirus type 16/18 ASO4-adjuvanted vaccine in Japanese women aged 20 to 25 years : final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010 ; 20 : 847-55
 
8) Munoz N, Manalastas R Jr, Pitisuttithum P, et al : Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years : a randomised, double-blind trial. Lancet 2009 ; 373 : 1949-57
 
9) Markowitz LE, Dunne EF, Saraiya M, et al : Quadrivalent Human Papillomavirus Vaccine : Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 ; 56 : 1-24
 
10) Naud P, et al : HPV-16/18 vaccine : Sustained immunogenicity and efficacy up to 9.4 years. 27th International Papillomavirus Conference 2011, Berlin, Germany
 
11) Brown DR, Kjaer SK, Slgurdsson K, et al : The impact of quadrivalent human papillomavirus (HPV, types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199 : 926-35
 

第IV章 治療と今後の展望

P.52 掲載の参考文献
1) 平成20年度厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班, 平成21年度厚生労働省がん研究助成金「がん検診の評価とあり方に関する研究」班 : 有効性評価に基づく子宮頸がん検診ガイドライン. 2009
 
2) Ronco G, Glorgl-Rossi P, carozzl F, et al : Efflcacy of human papillomavirus testing for the detection of invaslve cervical cancers and cervical intraepithelial neopiasia : a randomised controlled trial. Lancet Oncol. 2010 ; 11 : 249-57
 
3) Rijkaart DC, Berkhof J, Rozendaal L, et al : Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer : final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012 ; 13 : 78-88
PubMed
4) 日本産婦人科医会 : 子宮頸がん検診リコメンデーションとHPVワクチンの普及に向けて. 2011
 
5) Zorzi M, Del Mistro A, Farruggio A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme : a population-based cohort study. BJOG 2013 ; 120 : 1260-7
 
P.54 掲載の参考文献
1) 社団法人京都府医師会子宮がん検診 40周年記念誌 (平成24年3月)
 
2) 平成22年度厚生労働省地域保健・健康増進事業報告
 
3) 平成24年度京都府がん検診受診率調査報告書
 
4) 平成23年度文部科学省学校基本調査
 
P.57 掲載の参考文献
1) 日本婦人科腫瘍学会編子宮頸癌治療ガイドライン 2011年版. 東京, 金原出版, 2011
 
2) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会, 日本放射線腫瘍学会編 : 子宮頸癌取扱い規約第3版. 東京, 金原出版, 2012
 
3) 小林裕明 : 早期子宮頸癌に対する妊孕性温存療法-妊娠合併子宮頸癌の取扱いを含めて. 産科と婦人科 2013 ; 80 : 1317-24
 
4) Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al : Obstetric outcome after conservative treatment for intraepithelial or early invasive cervical lesion : systemic review and meta-analysis, Lancet 2006 ; 367 : 489-98
PubMed
5) Nishio H, Fujii T, Kameyama K, et al : Abdominal radical trachelectomy as a fertility-sparing procedure in women with early stage cervical cancer in a series of 61 women. Gynecol Oncol 2009 ; 115 : 51-5
 
6) Sato S, Aoki D, Kobayashi H, et al : Questionnaire survey of the current status of radical trachelectomy in Japan. Int J Clin Oncol 2011 ; 16 : 141-4
PubMed
7) 小林裕明 : 当科における腹式子宮頸部摘出術の適格基準と疾病予後について. 日本婦人科腫瘍学会雑誌 2011 ; 29 : 668-74
 
8) Ogawa S, Kobayashi H, Amada S, et al : Sentinel node detection with (99m) Tc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy. Int J Clin Oncol 2010 ; 15 : 52-8
 
9) 小林裕明 : 広汎性子宮頸部摘出術における工夫 : 子宮頸部摘出術後の妊娠・分娩に関する問題点. 産婦人科手術 2010 ; 21 : 59-68
 
P.59 掲載の参考文献
1) Wright TC Jr, Massad LS, Dunton CJ, et al : 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. Am J Obstet Gynecol 2007 ; 197 : 340-5
 
2) American College of Obstetricians and Gynecologists : ACOG Practice Bulletin No. 99 : Management of abnormal cervical cytology and histology. Obstet Gynecol 2008 ; 112 : 1419-44
 
3) Kennedy AW, Biscotti CV : Further study of the management of cervical adenocarcinoma in situ. Gynecol Oncol 2002 ; 86 : 361-4
 
4) Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al : Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006 ; 367 : 489-98
PubMed
5) Ostor AG : Natural history of cervical intraepithelial neoplasia : a critical review. Int J Gynecol Pathol 1993 ; 12 : 186-92
 
P.61 掲載の参考文献
1) Spitzer M, Brotzman GL, Apgar BS : Practical therapeutic options for treatment of cervical intraepithelial neoplasia : Im Colposcopy Principles and Practice, 2nd edition, Eds Apgar, BS, Brotzman GL, Spitzer M, 2007, 505-20
 
2) 藤井多久磨, 西尾浩, 平尾薫丸ほか : CIN局所療法の選択とその適応について. 産婦人科の実際 2010 ; 59 : 473-8
 
3) 藤井多久磨, 西尾浩, 杉山樹里ほか : 子宮頸癌の治療と生殖医療の役割. 産科と婦人科 2011 ; 78 : 332-5
 
P.64 掲載の参考文献
1) Ushijlma K : Current status of gynecologic cancer in Japan. J Gynecol Oncol 2009 ; 20 : 67-71
 
2) Smith LH, Dalrymple JL, Lelserowitz GS, et al : Obstetrlcal deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001 ; 184 : 1504-12
 
3) Smith LH, Danielsen B, Allen ME, et al : Cancer associated with obstetric delivery : results of linkage with the california cancer registry. Am J Obstet Gynecol 2003 ; 189 : 1128-35
 
4) Hopkins MP, Morley GW : The prognosis and management of cervical cancer associated with pregnancy. Obstet Gynecol 1992 ; 80, 9-13
PubMed
5) 日本産科婦人科学会 : CQ502 妊娠初期の子宮頸部細胞診異常の取り扱いは? 産婦人科診療ガイドライン産科編 pp.224-8, 2011
 
6) Ueda Y, Enomoto T, Miyatake T, et al : Postpartum outcome of cervical intraepithelial neoplasia in pregnant women determined by route of delivery Reprod Sci 2009 ; 16 : 1034-9
 
7) Hunter MI, Monk BJ, Tewari KS : Cervical neoplasia in pregnancy. Part 1 : screening and management of preinvasive disease. Am J Obstet Gynecol 2008 ; 199 : 3-9
 
8) Flannelly G : The management of women with abnormal cervical cytology in pregnancy. Clin Obstet Gynecol 2010 ; 24 : 51-60
 
9) Robinson WR, Webb 5, Tirpack J, et al : Management of cervical intraepithelial neoplasia during pregnancy with LOOP excision. Gynecol Oncol 1997 ; 64 : 153-5
 
10) Sood AK, Sorosky JI, Krogman S, et al : Surgical management of cervical cancer compllcating pregnancy : a case-control study. Gynecol Oncol 1996 ; 63, 294-8
 
11) Sood AK, Sorosky JI, Mayr N, et al : Radiotherapeutic management of cervical carcinoma that complicates pregnancy. Cancer 1997 ; 80 : 1073-8
 
12) Takushi M, Moromizato H, Sakumoto K, et al : Management of invasive carcinoma of the uterine cervix associated with pregnancy : outcome of intentional delay in treatment. Gynecol Oncol 2002 ; 87 : 185-9
 
13) Allen Mc, Donohue PK, Dusman AE : The limit of vlability--neonatal outcome of lnfants born at 22 to 25 weeks' gestation N Engl J Med 1993 ; 329 : 1597-601
 
14) Sorosky JI, Squatrjto R, Ndubisi BU, et al : Stage 1 squamous cell cervical carcinoma in pregnancy : planned delay in therapy awaiting fetal maturity. Gynecol Oncol 1995 ; 59 : 207-10
 
15) Greer BE, Easterling TR, McLennan DA, et al : Fetal and maternal considerations in the management of stage I-B cervical cancer during pregnancy. Gynecol Oncol 1989 ; 34 : 61-5
 
16) Fruscio R, Villa A, Chiari S, et al : Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy : a series of nine cases and literature review. Gynecol Oncol 2012 ; 126 : 192-7
 
17) LI J, Wang LJ, Zhang BZ, et al : Neoadjuvant chemotherapy with paciltaxel plus platinum for invaslve cervical cancer in pregnancy : two case report and literature review, Arch Gynecol Obstet 2011 ; 284 : 779-83
 
18) Koc ON, McFee M, Reed E, et al : Detection of platinum-DNA adducts in cord blood lymphocytes following in utero platinum exposure, Eur J Cancer 1994 ; 30A : 716-7
 
19) Diwan BA, Anderson LM, Rehm S, et al : Transplacental carcinogenicity of cisplatin : initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice. Cancer Res 1993 ; 53 : 3874-6
 
20) Diwan BA, Anderson LM, Ward JM, et al : Transplacental carcinogenesis by cisplatin in F344/NCr rats : promotion of kidney tumors by postnatal administration of sodium barbital, Toxicol Appl Pharmacol 1995 ; 132 : 115-21
 
21) Mir O, Berveiller P, Ropert S, et al : Use of platinum derivatives during pregnancy. Cancer 2008 ; 113 : 3069-74
 
22) Enomoto T, Yoshino K, Fujita M, et al : A successful case of abdominal radical trachelectomy for cervical cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol 158 : 365-6
 
23) Iwami N, Ishioka S, Endo T, et al : First case of vaginal radical trachelectomy in a pregnant Japanese woman. Int J Clin Oncol 2011 ; 16 : 737-40
 
P.65 掲載の参考文献
1) 万代昌紀 : 子宮頸部広汎性手術をめぐって : 神経温存, 頸部摘出, 腹腔鏡・ロボット手術. 日産婦誌 2013 ; 65 : 1253-8
 
2) 万代昌紀, 小阪謙三, 馬場長ほか : 子宮頸癌に対するロボット手術. 産婦人科の実際 2013 ; 62 : 33-8
 
3) 万代昌紀, 小阪謙三, 馬場長ほか : 子宮頸部浸潤癌に対するロボット支援下神経温存広汎子宮全摘術の導入. 日本婦人科腫瘍学会雑誌 2013 ; 31 : 152-4
 
P.67 掲載の参考文献
1) Keys HM, Bundy BN, Stehman FB, et al : Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 1999 ; 340 : 1154-61
 
2) Morris M, Eifel PJ, Lu J, et al : Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 1999 ; 340 : 1137-43
PubMed
3) Kim JY, Kim JH, Yoon MS, et al : Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases. Int J Radiat Oncol Biol Phys 2012 ; 84 : 741-7
 
4) Bazhenov AG, Guseinov KD, Khadzhimba AV, et al : Results of treatment for recurrent cancer of the uterine cervix. Vopr Onkol 2009 ; 55 : 319-26
PubMed
5) Wang CJ, Lai CH, Huang HJ, et al : Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 1999 ; 181 : 518-24
 
6) Russell AH, Koh WJ, Markette K, et al : Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract, Gynecol Oncol 1987 ; 27 : 226-32
PubMed
7) Xiang-E W, Shu-mo C, Ya-qin D, et al : Treatment of late recurrent vaginal malignancy after initial radiotherapy for carcinoma of the cervix : an analysis of 73 cases. Gynecol Oncol 1998 ; 69 : 125-9
 
8) Rosa DD, Medeiros LR, Edelweiss MI, et al : Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 2009 ; (3) : CD005342
PubMed
9) Shibata K, Kajiyama H, Yamamoto E, et al : Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix. Eur J Surg Oncol 2009 ; 35 : 768-72
 
10) Emstein MH, Novetsky AP, Garg M, et al : Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer Cancer 2007 ; 109 : 48-53
 
11) Ryu SY, Lee WM, Kim K, et al : Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2011 ; 81 : e577-81
PubMed
12) Schefter TE, Winter K, Kwon JS, et al : A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinomal preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 2012 ; 83 : 1179-84
 
13) Kirwan JM, Symonds P, Green JA, et al : A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003 ; 68 : 217-26
PubMed
14) Groopman JE, Itri LM : Chemotherapy-induced anemia in adults : incidence and treatment. J Natl Cancer Inst, 1999 ; 91 : 1616-34
 
15) Grogan M, Thomas GM, Melamed I, et al : The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999 ; 86 : 1528-36
 
16) 日本婦人科腫瘍学会編. 子宮頸癌治療ガイドライン2011年版. 金原出版, 東京, pp. 110-11, 2011
 
P.71 掲載の参考文献
1) Lehtinen M, Paavonen J, Wheeler CM, et al : Overall efficacy of HPV-16/18 ASO4-adjuvanted vaccinee against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 ; 13 : 89-99
 
2) Wheeler CM, Castellsague X, Garland SM, et al : Cross-protective efficacy of HPV-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 ; 13 : 100-10
 
3) 森澤宏行, 藤原寛行, 鈴木光明ほか : 子宮頸癌およびcervical intraepithelial neplasia 3 (CIN3) 症例のがん検診歴に関する検討. 日臨細胞学会誌 2012 ; 51 : 164-8
 
4) Xu JY, Hashi A, Kondo T, et al : Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol 2005 ; 24 : 296-302
 
5) Nara M, Hashi A, Murata S, et al : Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol 2007 ; 106 : 289-98
 
6) Ochi H, Kondo K, Matsumoto K, et al : Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 2008 ; 15 : 1536-40
PubMed

書評

最近チェックした商品履歴

Loading...